Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA. Poster presentation details: Title: PPAR-α Antagonist Enhances Immunotherapy and Anti Angiogenic Therapy to Inhibit Murine Renal Cancer Abstract Number: 3045 Date & Time: Monday, April 8, 2024; 1:30 – 5:00 p.m. PT Session Title: Oncogenic Transcription Factors Location: Poster Section 18 All regular abstracts are available for viewing via AACR’s online itinerary planner, located here . About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com . Investor & Media Contacts Sylvia Wheeler Wheelhouse Life Science Advisors [email protected] Aljanae Reynolds Wheelhouse Life Science Advisors [email protected] i If approved by the FDA © 2026 Tempest Therapeutics. All rights reserved. var s_CCSWebHostingAccount = "trcgtempesttherapeutics"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/10061","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkeFuQyEIhV-ouTbN3oegstZdhRug2_r2tbqk7bJliz8U_ORwkIsCMtaLl2SBH6MFs0SCimdOpx3_CW4qeWARjQZRkrA9p1ykRtSRTCvl4qKQ0fuKlSzcj8urCjvxrNlQV_JBQqyS1jDkzUHRCx-7Qi94QvV_4QZD5Be2ETIoJWmt6_cHwo-1z9VL661jeA7H7YbH6fR2WPANPwFzhlTRDLCSuv3ApWHVwS6cuhVmmiPaSn45HPZB3km15NnwB0UrTsDSp0_zM77llq99Z90ztXCb_xUmCsI1","theme":"nir_pid4220","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"e4cd9886b98324d3a81033a7e8a58e5b662d9828a13ae2363f42a309d045dd8e"}}

The release as fetched from its publisher. tempesttx.com ↗